Impact News +++ Ad-hoc News: Gerresheimer AG (EQS) +++ GERRESHEIMER Aktie -4,16%

TALPHERA Aktie

>TALPHERA Aktienkurs

0.35675 EUR (Tradegate)

Ask: 0.368 EUR / 4100 Stück

Bid: 0.3455 EUR / 4400 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 8 bis 22 Uhr!

TALPHERA Aktie über LYNX handeln

Intraday

1 Jahr

>TALPHERA Performance

1 Woche: -6,3%

1 Monat: -8,7%

3 Monate: -9,9%

6 Monate: -28,9%

1 Jahr: -53,1%

laufendes Jahr: -22,1%

>TALPHERA Aktie

Name:

TALPHERA INC. DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US00444T2096 / A3DWPN

Symbol/ Ticker:

R5XA (Frankfurt) / TLPH (NASDAQ)

Kürzel:

FRA:R5XA, ETR:R5XA, R5XA:GR, NASDAQ:TLPH

Index:

Webseite:

https://talphera.com/

Marktkapitalisierung:

9.06 Mio. EUR

Umsatz:

0.02 Mio. EUR

EBITDA:

Gewinn je Aktie:

-0.329 EUR

Schulden:

5.65 Mio. EUR

Liquide Mittel:

4.67 Mio. EUR

Umsatz-/ Gewinnwachstum:

- / -

KGV/ KGV lG:

0.2 / -

KUV/ KBV/ PEG:

486.38 / 1.83 / -

Gewinnm./ Eigenkapitalr.:

- / -106.83%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

TALPHERA, ACELRX

Letzte Datenerhebung:

16.07.25

>TALPHERA Eigentümer

Aktien: 20.5 Mio. St.

f.h. Aktien: 18.02 Mio. St.

Insider Eigner: 2.64%

Instit. Eigner: 31.31%

Leerverk. Aktien: 1.41%

>TALPHERA Peer Group

ARMATA

CLINUVEL ADR

CO-DIAGNOSTICS

INNOVIVA

KODIAK SCIENCES

LABCORP

OMEROS

SCYNEXIS

SPYRE THERAPEUTICS

VAREX IMAGING

>TALPHERA Chart & Kurs - NASDAQ

>TALPHERA News

15.05.25 - 03:06	Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.25 - 22:12	Talphera GAAP EPS of -$0.10 beats by $0.05 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.25 - 22:09	Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
	Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million Three new clinical study sites activated and screening patients thus far in 2025, with five additional......

07.05.25 - 22:06	Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 (PR Newswire)
	SAN MATEO, Calif., May 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first......

06.05.25 - 19:30	All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy (Zacks)
	Talphera (TLPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....

04.04.25 - 19:45	Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
	Talphera (TLPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

04.04.25 - 02:01	Insiderhandel: CHIEF EXECUTIVE OFFICER kauft Aktien von Talphera im Wert von 125000 USD (Insiderkauf)
	Angotti, Vincent J. - Vorstand - Tag der Transaktion: 2025-04-02...

01.04.25 - 00:42	Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.03.25 - 22:09	AcelRx Pharmaceuticals GAAP EPS of -$0.07 beats by $0.09 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.03.25 - 22:06	Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (PR Newswire)
	The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 Talphera expects the registrational NEPHRO CRRT study to be completed by the end of 2025 Cash and investments at December 31, 2024 of $8.9 million, together with the......

30.03.25 - 23:39	AcelRx Pharmaceuticals Q4 2024 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

26.03.25 - 21:39	Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025 (PR Newswire)
	SAN MATEO, Calif., March 26, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release fourth......

14.01.25 - 14:30	Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study (PR Newswire)
	Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week The FDA agreed to two additional protocol changes expected to accelerate enrollment in the NEPHRO CRRT study SAN MATEO, Calif., Jan. 14, 2025......

06.12.24 - 17:52	Insiderhandel: CHIEF EXECUTIVE OFFICER kauft Aktien von Talphera im Wert von 3200 USD (Insiderkauf)
	Angotti, Vincent J. - Vorstand - Tag der Transaktion: 2024-12-05...

03.12.24 - 03:01	Insiderhandel: Chief Financial Officer verkauft Aktien von Talphera im Wert von 119 USD (Insiderkauf)
	Asadorian, Raffi - Vorstand - Tag der Transaktion: 2024-12-02...

03.12.24 - 03:01	Insiderhandel: CHIEF EXECUTIVE OFFICER kauft Aktien von Talphera im Wert von 3650 USD (Insiderkauf)
	Angotti, Vincent J. - Vorstand - Tag der Transaktion: 2024-11-27...

13.11.24 - 22:12	AcelRx Pharmaceuticals GAAP EPS of -$0.13 beats by $0.07 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.24 - 22:07	Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
	Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter totaling seven active sites Cash and investments at September 30, 2024 of $11.1 million Conference call and webcast to be held......

12.11.24 - 23:36	AcelRx Pharmaceuticals Q3 2024 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.11.24 - 22:07	Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024 (PR Newswire)
	SAN MATEO, Calif., Nov. 6, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Vollkommene Politik besteht darin, niemals das letzte Motiv zu enthüllen. - Benjamin Disraeli

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram